List of Rapivab drug patents
Rapivab is owned by Biocryst.
Rapivab contains Peramivir.
Rapivab has a total of 3 drug patents out of which 0 drug patents have expired.
Rapivab was authorised for market use on 19 December, 2014.
Rapivab is available in solution;intravenous dosage forms.
Rapivab can be used as treatment of acute uncomplicated influenza in patients 2 years and older; treatment of acute uncomplicated influenza in adults; treatment of acute uncomplicated influenza in patients 6 months and older, treatment of acute uncomplicated influenza in patients 2 years and older; treatment of acute uncomplicated influenza in patients 6 months and older.
The generics of Rapivab are possible to be released after 07 May, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6562861 | BIOCRYST | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
Dec, 2023
(10 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10391075 | BIOCRYST | Antiviral treatments |
Feb, 2027
(4 years from now) | |
| US8778997 | BIOCRYST | Antiviral treatments |
May, 2027
(4 years from now) | |
Drugs and Companies using PERAMIVIR ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of acute uncomplicated influenza in patients 2 years and older; Treatment of acute uncomplicated influenza in patients 6 months and older; Treatment of acute uncomplicated influenza in adults
Dosage: SOLUTION;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic